title: Mequinol 2%/tretinoin 0.01% solution: an effective and safe alternative to hydroquinone 3% in the treatment of solar lentigines.
abstract: A new topical solution containing 4-hydroxyanisole (mequinol) 2%/tretinoin 0.01% (Solagé) was compared with its active components, its vehicle, and hydroquinone (HQ) 3% in the treatment of solar lentigines. In a randomized, parallel-group, double-masked study, 216 subjects applied the treatments twice daily for 16 weeks and were followed up for a further 24 weeks. A significantly higher proportion (P < or = .05) of subjects achieved clinical success with mequinol 2%/tretinoin 0.01% compared with HQ 3% as measured by both the lesional pigmentation on the forearm and the physician global assessment at the end of treatment. The proportion of subjects achieving clinical success on the face in the mequinol 2%/tretinoin 0.01% group was consistently higher than that in the HQ 3% group. Some treatment effects remained at the end of the treatment-free follow-up, with trends apparent on the face in favor of mequinol 2%/tretinoin 0.01% over HQ 3%. In all treatment groups, skin-related adverse events were mild or moderate and transient. In conclusion, the mequinol 2%/tretinoin 0.01% solution is a highly effective and well-tolerated treatment for solar lentigines and related hyperpigmented lesions, being superior to HQ 3% for lesions on the forearm and of similar efficacy for lesions on the face.
authors.affiliation: Derm Research Associates, Austin, Texas 78759, USA. mhaile@dermresearch.net
authors.forename: Michael
authors.initials: M
authors.lastname: Jarratt
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000840:Anisoles / Q000008:administration & dosage; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005145:Face; D005260:Female; D005542:Forearm; D006801:Humans; D006873:Hydroquinones / Q000008:administration & dosage; D007641:Keratolytic Agents / Q000008:administration & dosage*; D007911:Lentigo / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D014212:Tretinoin / Q000008:administration & dosage
chemical_list: D000840:Anisoles; D006873:Hydroquinones; D007641:Keratolytic Agents; D014212:Tretinoin; C009760:mequinol; C031927:hydroquinone